SAGENT PHARMA - Trademark Details
Status: 606 - Abandoned - No Statement Of Use Filed
Image for trademark with serial number 77256642
Serial Number
77256642
Word Mark
SAGENT PHARMA
Status
606 - Abandoned - No Statement Of Use Filed
Status Date
2012-08-06
Filing Date
2007-08-16
Mark Drawing
4000 - Standard character mark Typeset
Published for Opposition Date
2009-10-13
Law Office Assigned Location Code
M70
Employee Name
SWAIN, MICHELE LYNN
Statements
Disclaimer with Predetermined Text
"PHARMA"
Goods and Services
Pharmaceuticals, namely, alkalizing agents, analgesics and anesthetics, antacids, anticholinergics, antihistamines, anti-infectives, anti-inflammatory agents, anticonvulsants, antidotes, antiemetics, antipsychotics, anxiolytics, blood modifiers, bronchodialators, cardiovasculars, diuretics, hormones, diluents, electrolytes, vitamins, oncolytics, immunosuppressive agents, transplantation agents, imaging agents, vascular targeting agents, and sensitizing agents for chemotherapy-resistant tumors; Pre-filled syringes sold filled with alkalizing agents; pre-filled syringes sold filled with analgesics; pre-filled syringes sold filled with anesthetics; pre-filled syringes sold filled with antacids; pre-filled syringes sold filled with anticholinergics; pre-filled syringes sold filled with antihistamines; pre-filled syringes sold filled with anti-infectives; pre-filled syringes sold filled with anti-inflammatory agents; pre-filled syringes sold filled with anticonvulsants; pre-filled syringes sold filled with antidotes; pre-filled syringes sold filled with antiemetics; pre-filled syringes sold filled with antipsychotics; pre-filled syringes sold filled with anxiolytics; pre-filled syringes sold filled with blood modifiers; pre-filled syringes sold filled with bronchodialators; pre-filled syringes sold filled with cardiovasculars; pre-filled syringes sold filled with diuretics; pre-filled syringes sold filled with hormones; pre-filled syringes sold filled with diluents; pre-filled syringes sold filled with electrolytes; pre-filled syringes sold filled with vitamins; pre-filled syringes sold filled with oncolytics; pre-filled syringes sold filled with immunosuppressive agents; pre-filled syringes sold filled with transplantation agents; pre-filled syringes sold filled with imaging agents; pre-filled syringes sold filled with vascular targeting agents; pre-filled syringes sold filled with sensitizing agents for chemotherapy-resistant tumors; Safety syringe devices sold filled with alkalizing agents; safety syringe devices sold filled with analgesics; safety syringe devices sold filled with anesthetics; safety syringe devices sold filled with antacids; safety syringe devices sold filled with anticholinergics; safety syringe devices sold filled with antihistamines; safety syringe devices sold filled with anti-infectives; safety syringe devices sold filled with anti-inflammatory agents; safety syringe devices sold filled with anticonvulsants; safety syringe devices sold filled with antidotes; safety syringe devices sold filled with antiemetics; safety syringe devices sold filled with antipsychotics; safety syringe devices sold filled with anxiolytics; safety syringe devices sold filled with blood modifiers; safety syringe devices sold filled with bronchodialators; safety syringe devices sold filled with cardiovasculars; safety syringe devices sold filled with diuretics; safety syringe devices sold filled with hormones; safety syringe devices sold filled with diluents; safety syringe devices sold filled with electrolytes; safety syringe devices sold filled with vitamins; safety syringe devices sold filled with oncolytics; safety syringe devices sold filled with immunosuppressive agents; safety syringe devices sold filled with transplantation agents; safety syringe devices sold filled with imaging agents; safety syringe devices sold filled with vascular targeting agents; safety syringe devices sold filled with sensitizing agents for chemotherapy-resistant tumors; Pharmaceuticals for treatment of cancer; pharmaceuticals to treat vascular diseases; Drug delivery systems sold as an integral component of drugs, namely, intradermal injection system for injection of anesthetics; Injectable drugs and therapeutic solutions for the treatment of cancer and vascular diseases; injectable drugs and therapeutic solutions for the treatment of psychotic disorders; injectable drugs and therapeutic solutions for the treatment of pain; injectable drugs and therapeutic solutions for the treatment of allergies; injectable drugs and therapeutic solutions for the treatment of infections; injectable drugs and therapeutic solutions for the treatment of cardiovascular disease; injectable drugs and therapeutic solutions for the treatment of kidney disease; injectable drugs and therapeutic solutions for the treatment of hormonal imbalances; injectable drugs and therapeutic solutions for the treatment of vitamin deficiencies; injectable drugs and therapeutic solutions for the treatment of electrolyte deficiencies; injectable drugs and therapeutic solutions for the treatment of heartburn; injectable drugs and therapeutic solutions for the treatment of anxiety; injectable drugs and therapeutic solutions for immunosuppression; injectable drugs and therapeutic solutions for imaging; injectable drugs and therapeutic solutions for the treatment of seizures; Injectable drugs and therapeutic solutions for the treatment of cancer and vascular diseases sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of psychotic disorders sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of pain sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of allergies sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of infections sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of cardiovascular disease sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of kidney disease sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of hormonal imbalances sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of vitamin deficiencies sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of electrolyte deficiencies sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of heartburn sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of anxiety sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for immunosuppression sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for imaging sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of seizures sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2007-08-20
Primary Code
005
Correspondences
Name
MARCIA IRELAND ROSENFELD
Address
Please log in with your Justia account to see this address.
Trademark Events
Event DateEvent Description
2007-08-20NEW APPLICATION ENTERED IN TRAM
2007-11-26ASSIGNED TO EXAMINER
2007-11-27NON-FINAL ACTION WRITTEN
2007-11-27NON-FINAL ACTION E-MAILED
2007-11-27NOTIFICATION OF NON-FINAL ACTION E-MAILED
2008-05-27TEAS RESPONSE TO OFFICE ACTION RECEIVED
2008-05-27CORRESPONDENCE RECEIVED IN LAW OFFICE
2008-05-27TEAS/EMAIL CORRESPONDENCE ENTERED
2008-06-03SUSPENSION LETTER WRITTEN
2008-06-03LETTER OF SUSPENSION E-MAILED
2008-06-03NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
2008-12-04ASSIGNED TO LIE
2008-12-04REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
2009-06-06REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
2009-09-10APPROVED FOR PUB - PRINCIPAL REGISTER
2009-09-10LAW OFFICE PUBLICATION REVIEW COMPLETED
2009-10-13PUBLISHED FOR OPPOSITION
2009-10-13OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2010-01-05NOA MAILED - SOU REQUIRED FROM APPLICANT
2010-06-28TEAS EXTENSION RECEIVED
2010-06-28EXTENSION 1 FILED
2010-06-28EXTENSION 1 GRANTED
2010-06-30NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2011-01-03TEAS EXTENSION RECEIVED
2011-01-27CASE ASSIGNED TO INTENT TO USE PARALEGAL
2011-01-03EXTENSION 2 FILED
2011-01-27EXTENSION 2 GRANTED
2011-01-28NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2011-07-01TEAS EXTENSION RECEIVED
2011-07-01EXTENSION 3 FILED
2011-07-05EXTENSION 3 GRANTED
2011-07-06NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2011-10-05AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
2011-12-28TEAS EXTENSION RECEIVED
2011-12-28EXTENSION 4 FILED
2012-01-04EXTENSION 4 GRANTED
2012-01-05NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2012-08-06ABANDONMENT - NO USE STATEMENT FILED
2012-08-06ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED